Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia

IMPORTANCE: Among children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia, the rate of 5-year disease-free survival is 10% to 20%. Approval of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, represents a new and potentially curative treatment option. H...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Pediatr
Autors principals: Whittington, Melanie D., McQueen, R. Brett, Ollendorf, Daniel A., Kumar, Varun M., Chapman, Richard H., Tice, Jeffrey A., Pearson, Steven D., Campbell, Jonathan D.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2018
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6583018/
https://ncbi.nlm.nih.gov/pubmed/30304407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamapediatrics.2018.2530
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars